Delayed β-cell response and glucose intolerance in young women with Turner syndrome

BMC Endocrine Disorders

Volumn 11, Issue , 2011, Pages

  Hjerrild, Britta E ^a   Holst, Jens J ^b   Juhl, Claus B ^c   Christiansen, Jens S ^a   Schmitz, Ole ^a   Gravholt, Claus H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROCORTISONE; INSULIN; NORADRENALIN; SOMATOMEDIN C;

ADULT; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY EXPENDITURE; ENTROPY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MUSCLE MASS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; TURNER SYNDROME; WAIST HIP RATIO;

EID: 79952557795     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-11-6     Document Type: Article

References (37)

1. Forbes AP, Engel E. The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metabolism 1963, 12:428-439.
2. Nielsen J, Johansen K, Yde H. The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinol Copenh 1969, 62:251-269.
3. Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, Amiel S, Press M, Tamborlane WV. Insulin resistance: an early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 1991, 72:832-836. 10.1210/jcem-72-4-832, 2005209.
4. Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. Diabetes Care 1998, 21:1062-1070. 10.2337/diacare.21.7.1062, 9653596.
5. Bakalov VK, Cooley MM, Quon MJ, Luo ML, Yanovski JA, Nelson LM, Sullivan G, Bondy CA. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004, 89:3516-3520. 10.1210/jc.2004-0122, 15240640.
6. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998, 51:147-158. 10.1016/S0895-4356(97)00237-0, 9474075.
7. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in women with turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab 2008, 93:4735-4742. 10.1210/jc.2008-1049, 18812477.
8. Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006, 91:3897-3902. 10.1210/jc.2006-0558, 16849410.
9. Salgin B, Amin R, Yuen K, Williams RM, Murgatroyd P, Dunger DB. Insulin resistance is an intrinsic defect independent of fat mass in women with Turner's syndrome. Horm Res 2006, 65:69-75. 10.1159/000090907, 16407654.
10. Abrahamsen B, Gram J, Hansen TB, Beck NH. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. Bone 1995, 16:385-390. 10.1016/8756-3282(94)00054-9, 7786643.
11. Ferrannini E. Equations and assumptions of indirect calorimetry: some special problems. 1992, 1-17.
12. Tripathy D, Wessman Y, Gullstrom M, Tuomi T, Groop L. Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test: results with the Botnia clamp. Diabetes Care 2003, 26:1395-1401. 10.2337/diacare.26.5.1395, 12716795.
13. Veldhuis JD, Carlson ML, Johnson ML. The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA 1987, 84:7686-7690. 10.1073/pnas.84.21.7686, 299365, 2823271.
14. Porksen N, Nyholm B, Veldhuis JD, Butler PC, Schmitz O. In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts. Am J Physiol 1997, 273:E908-14.
15. Pincus SM. Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA 1991, 88:2297-2301. 10.1073/pnas.88.6.2297, 51218, 11607165.
16. Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 1995, 5:169-176.
17. Carstensen E, Yudkin JS. Platelet catecholamine concentrations after short-term stress in normal subjects. Clin Sci (Lond) 1994, 86:35-41.
18. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 1994, 43:104-108. 10.1016/0026-0495(94)90164-3, 8289665.
19. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85:3575-3581. 10.1210/jc.85.10.3575, 11061504.
20. Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 2001, 86:4166-4170. 10.1210/jc.86.9.4166, 11549644.
21. Ostberg JE, Attar MJ, Mohamed-Ali V, Conway GS. Adipokine dysregulation in Turner syndrome: comparison of circulating interleukin-6 and leptin concentrations with measures of adiposity and C-reactive protein. J Clin Endocrinol Metab 2005, 90:2948-2953. 10.1210/jc.2004-1966, 15728208.
22. Stoppoloni G, Prisco F, Alfano C, Iafusco D, Marrazzo G, Paolisso G. Characteristics of insulin resistance in Turner syndrome. Diabete Metab 1990, 16:267-271.
23. Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab 2009, 94:3289-3296. 10.1210/jc.2009-0384, 2741724, 19567529.
24. Vilsboll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000, 23:807-812. 10.2337/diacare.23.6.807, 10841001.
25. Holl RW, Kunze D, Etzrodt H, Teller W, Heinze E. Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediatr 1994, 153:11-16. 10.1007/BF02000780, 8313917.
26. Gravholt CH, Leth-Larsen R, Lauridsen AL, Thiel S, Hansen TK, Holmskov U, Naeraa RW, Christiansen JS. The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. Eur J Endocrinol 2004, 150:355-362. 10.1530/eje.0.1500355, 15012622.
27. Mortensen KH, Cleemann L, Hjerrild BE, Nexo E, Locht H, Jeppesen EM, Gravholt CH. Increased prevalence of autoimmunity in Turner syndrome--influence of age. Clin Exp Immunol 2009, 156:205-210. 10.1111/j.1365-2249.2009.03895.x, 2759466, 19298606.
28. Jorgensen KT, Rostgaard K, Bache I, Biggar RJ, Nielsen NM, Tommerup N, Frisch M. Autoimmune diseases in women with Turner's Syndrome. Arthritis Rheum 2010, 62:658-666. 10.1002/art.27270, 20187158.
29. Bianco B, Verreschi IT, Oliveira KC, Guedes AD, Galera BB, Galera MF, Barbosa CP, Lipay MV. PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome. Scand J Immunol 2010, 72:256-259. 10.1111/j.1365-3083.2010.02438.x, 20696024.
30. Gravholt CH, Frystyk J, Flyvbjerg A, Ørskov H, Christiansen JS. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am J Physiol 2001, 280:E308-E314.
31. Gravholt CH, Hjerrild BE, Mosekilde L, Hansen TK, Rasmussen LM, Frystyk J, Flyvbjerg A, Christiansen JS. Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol 2006, 155:583-592. 10.1530/eje.1.02267, 16990658.
32. Gravholt CH, Chen JW, Oxvig C, Overgaard MT, Christiansen JS, Frystyk J, Flyvbjerg A. The GH-IGF-IGFBP axis is changed in Turner syndrome: Partial normalization by HRT. Growth Horm IGF Res 2006, 16:332-339. 10.1016/j.ghir.2006.09.001, 17067837.
33. Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2008, 93:2109-2114. 10.1210/jc.2007-2266, 2435647,2435647, 18349057.
34. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008, 93:1702-1710. 10.1210/jc.2007-2193, 18303079.
35. Zuckerman-Levin N, Zinder O, Greenberg A, Levin M, Jacob G, Hochberg Z. Physiological and catecholamine response to sympathetic stimulation in turner syndrome. Clin Endocrinol (Oxf) 2006, 64:410-415. 10.1111/j.1365-2265.2006.02483.x, 16584513.
36. Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf) 1999, 51:497-502. 10.1046/j.1365-2265.1999.00841.x, 10583318.
37. Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003, 88:3794-3800. 10.1210/jc.2002-021181, 12915671.